IHC staining of the hBD-1 peptide in clinical specimens of both renal cell carcinoma and prostate cancer tissue revealed that >80% of the samples were either completely devoid of hBD-1 expression, or showed marginal expression when compared to adjacent benign epithelium (22). This evidence concerns the gene DEFB1 and Familial prostate cancer.